Literature DB >> 2164934

The effect of ketoconazole and transdermal estradiol on serum sex steroid hormones levels.

G S Hughes1, S F Francom, C R Spillers, T V Ringer.   

Abstract

In this randomized, open-label trial, 24 subjects were studied. There were 12 subjects with essential hypertension and 12 normotensive controls who received, after an initial control period, 48 h of treatment with a transdermal estradiol patch or ketoconazole tablets every 8 h for six doses, or in combination. LHRH (100 micrograms) and ACTH (250 micrograms) were given at 48 h of each treatment. Each treatment was one week apart. In both normotensive and hypertensive men ketoconazole reduced adrenal and gonadal androgens, raised 11-deoxycortisol and 17 alpha-hydroxyprogesterone levels; blunted the rise of cortisol to ACTH and had no effect on the response of LH to LHRH. Transdermal estradiol raised serum estradiol levels, blunted the time to peak plasma concentration of LH to LHRH and produced a normal response to ACTH. Although baseline level of total and free testosterone and DHEA-S were lower in hypertensive men, the response of the pituitary (LH) to LHRH and adrenal axis with ACTH were similar in both normotensive and hypertensive men. Blood pressure was unaffected by any of the treatment interventions in either normotensive or hypertensive men. Although ketoconazole or transdermal estradiol reduce androgens, there was no evidence that this reduction in androgens was involved with the short term regulation of blood pressure in hypertensive men.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164934     DOI: 10.1007/BF00278581

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  31 in total

1.  Biologic effects of transdermal estradiol.

Authors:  R J Chetkowski; D R Meldrum; K A Steingold; D Randle; J K Lu; P Eggena; J M Hershman; N K Alkjaersig; A P Fletcher; H L Judd
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

2.  Essential hypertension: renin and aldosterone, heart attack and stroke.

Authors:  H R Brunner; J H Laragh; L Baer; M A Newton; F T Goodwin; L R Krakoff; R H Bard; F R Bühler
Journal:  N Engl J Med       Date:  1972-03-02       Impact factor: 91.245

3.  Essential role of post-heparin lipoprotein lipase activity and of plasma testosterone in coronary artery disease.

Authors:  C Breier; V Mühlberger; H Drexel; M Herold; H J Lisch; E Knapp; H Braunsteiner
Journal:  Lancet       Date:  1985-06-01       Impact factor: 79.321

4.  Serum oestradiol and ischaemic heart disease--relationship with myocardial infarction but not coronary atheroma or haemostasis.

Authors:  M Small; G D Lowe; G H Beastall; J M Beattie; M McEachern; I Hutton; A R Lorimer; C D Forbes
Journal:  Q J Med       Date:  1985-11

5.  Serum estradiol and coronary artery disease.

Authors:  R J Goldberg; J M Gore; M Zive; P Brady; E Klaiber; D Broverman; I S Ockene; J E Dalen
Journal:  Am J Med       Date:  1987-01       Impact factor: 4.965

6.  Blood pressure and endogenous testosterone in men: an inverse relationship.

Authors:  K T Khaw; E Barrett-Connor
Journal:  J Hypertens       Date:  1988-04       Impact factor: 4.844

7.  Usefulness of sex steroid hormone levels in predicting coronary artery disease in men.

Authors:  J A Cauley; J P Gutai; L H Kuller; W S Dai
Journal:  Am J Cardiol       Date:  1987-10-01       Impact factor: 2.778

8.  Evidence for a role of endogenous estrogen in the hypothalamic control of gonadotropin secretion in men.

Authors:  S J Winters; P Troen
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

9.  Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort.

Authors:  G B Phillips; W P Castelli; R D Abbott; P M McNamara
Journal:  Am J Med       Date:  1983-05       Impact factor: 4.965

10.  Conversion of blood androgens to estrogens in normal adult men and women.

Authors:  C Longcope; T Kato; R Horton
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.